We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.80 | 2.06% | 39.70 | 39.15 | 39.80 | 39.35 | 38.85 | 39.05 | 315,724 | 16:35:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 3.1M | -6.51M | -0.0217 | -18.04 | 117.73M |
Date | Subject | Author | Discuss |
---|---|---|---|
11/5/2024 11:21 | Either MDI was up watching the Northern Lights or he was in Glavey's portakabin 'helping' with the night watchman duties! I mean, who else posts comments on FUM in the early hours of the morning apart from rabid stock bashers? | petroc | |
09/5/2024 19:35 | These are very basic A level accounting points and of no issue whatsoever for anyone who understands how financial accounting works. I took the trouble to explain this to you in more detail a while back so will not do so again :) So this attempt fails at making any argument that you imply. Please rest there genuinely - I know how desparate you are but there is a life to live... | takeiteasy | |
09/5/2024 19:26 | Really? So why are upfront payments contract liabilities? ‘upfront milestone payment which is to be recognised as a Contract Liability until satisfaction of the performance obligations’ Or ‘royalties not being recognised in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur’ And that ‘Futura will remain Legal Manufacturer’ and therefore can be held ‘responsible&r ‘Legal manufacturer means the organisation responsible for the design, manufacture, packaging and labelling of a device before it is placed on the market under that organisation's own name’ ‘Other variable considerations such as milestone payments and royalties are not recognised in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. In managements opinion, that will be when the Groups customer confirms that the milestone has been met or that a royalty is due’ | mdi | |
09/5/2024 19:18 | Who accepts this. Everyone who is closely allied to the business i.e. management, suppliers and sales network - they are all marketing the firm on this basis. There is simply no more to discuss on this matter. Anyway time for me to sign off again. | takeiteasy | |
09/5/2024 18:56 | This is simply so dull - we have had this argument 3 times - I accept the testing the firm has done (and so does everyone else) as a valid proxy for what is required. Yes, you can endlessly state the regulations but when the firm has done the level of testing it has done then that is more than sufficient given the acceptance from all parties bar a few whining medics .... You do not accept it - everyone knows you do not. So try another topic to discuss. | takeiteasy | |
09/5/2024 18:36 | approval to sell yes in USA is fine..does not have to mean more than that..you worry endlessly about the wrong issues. it is not a sham device so stop trying to wind everyone up...what you fail to understand is as I have said before everyone knows what you know ...so why repeat yourself 100 times over... | takeiteasy | |
09/5/2024 18:25 | MDI, it's impossible to underestimate you. | petroc | |
09/5/2024 17:57 | ‘Men with erectile dysfunction (ED) who were in the placebo arm of clinical trials of phosphodiesterase 5 inhibitors (PDE5Is) had significant improvement in erectile function’ ‘the placebo effect in RCT of iPDE5 for ED occurs at a rate as high as 50%’ ‘Recent research has shown that the placebo effect is not only similar for medical devices to medical trials; it is considerably larger, the effect of a sham device is almost three times that of an oral placebo’ Placebo Treatment: Don't Eat It, Rub it! ˜indications to suggest that a topical placebo induces stronger effects than an oral placebo’ | mdi | |
09/5/2024 15:40 | Of course the FDA is not going to offer any sort of warranty in the small print but that is standard legal practice and not worth jumping and down 100 times over. | takeiteasy | |
09/5/2024 15:37 | Futura Medical Shares Rise After FDA Approves Erectile Dysfunction Treatment 12/06/2023 8:44am Dow Jones News Please note the word approves.... | takeiteasy | |
09/5/2024 15:20 | Incorrect. Low class Medical devices like Eroxon do not get ‘approved&rsqu ‘Consumers may not be aware that, as the FDA explains, ‘Registration and Listing does not denote approval or clearance of a firm or their devices meaning that when you see ‘FDA registered’ or FDA listed’ in advertising it not indicative of the efficacy or safety of the product, no matter how much the marketer would like you to believe otherwise’ Dear Ken James: ‘FDA concludes that this device should be classified into Class II’ Page 3 Please be advised that FDA's decision to grant this De Novo request does not mean that FDA has made a determination that your device complies with other requirements of the FD&C Act or any Federal statutes and regulations administered by other Federal agencies In In terms of advertising and promotion, for most over-the-counter medical devices, the FDA and FTC exercise joint regulatory authority over product labelling and advertising. The FDA has primary jurisdiction over labelling for all medical devices and advertising for restricted devices (typically Class III), while FTC has primary jurisdiction over advertising of unrestricted medical devices (Class I and most Class II devices). The FDCA prohibits the distribution or receipt in interstate commerce of a misbranded medical device, which includes a device bearing false or misleading labelling. Claims in device labelling, including product websites, that are outside the scope of the device cleared uses can misbrand, and even adulterate the device, another prohibited act under the FDCA | mdi | |
09/5/2024 15:13 | The regulator has approved it and so has the sales network. End of. No one on the planet apart from a few moaning medics and you has the slightest interest. The more successful eroxon is the less money the medics will make from their fewer client consultations as this allows direct client access to treatment bypassing medics where appropriate- no wonder some medics are not going to be cheerful :) | takeiteasy | |
09/5/2024 13:51 | Yet the fact remains. Med3000 is still unable to support any of its claims or even its speed of onset claims with evidence from any double-blind, randomized, placebo-controlled clinical trial to substantiate any efficacy beyond just using any similar non medicated placebo hydroalcoholic gel. So medical device clearance process of Eroxon was only completed to the ‘flimsy’ ‘Its the gold standard in medicine: taking a treatment, and putting it head-to-head against a placebo to confidently declare whether it actually works. But for most medical (including Eroxon) devices, placebo trials have never been done’ Dear Ken James: Page 3 Please be advised that FDA's decision to grant this De Novo request does not mean that FDA has made a determination that your device complies with other requirements of the FD&C Act or any Federal statutes and regulations administered by other Federal agencies ‘The FTC and the Food and Drug Administration (FDA) share jurisdiction over the marketing of dietary supplements, foods, drugs, devices, and other health-related products’ | mdi | |
09/5/2024 13:48 | The question was about a definition of a product - not a research validation processs query. The US regulatory bodies approval process was in 2023 and completed. | takeiteasy | |
09/5/2024 13:47 | Could be also claimed Eroxon is the real ‘cut and past job’ exploiting men with ED? ‘The ingredients in Eroxon® gel ”ethanol,[1] propylene glycol,[2] glycerine (also known as glycerol),[3] carbomer[4] Costs €28.89 for 1.2ml or the equivalent of €2,407.50 / 100 ml Aia* stimulating gel €22,95 for 30ml or the equivalent of €76.50 / 100ml Our stimulating gel is made of water and glycerin, also the two main components of our neutral lubricant. We have added some extras to the stimulating gel. Propylene glycol is a safe synthetic substance with a moisturizing effect. Alcohol Denat or Denatured Alcohol is also often used in natural cosmetics: it dissolves essential oils in the product and it is used to extract certain extracts from plants. Carbomer is an emulsifier and thickener. It ensures that the gel remains a nice, even substance that spreads nicely. | mdi | |
09/5/2024 13:39 | No answer to the question - just repeat a cut and paste job... | takeiteasy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions